These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 27650464)
1. Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours. Macfarlane MJ; Macfarlane LL; Scase T; Parkin T; Morris JS Vet Rec; 2016 Nov; 179(19):491. PubMed ID: 27650464 [TBL] [Abstract][Full Text] [Related]
2. Association of breed and histopathological grade in canine mast cell tumours. Mochizuki H; Motsinger-Reif A; Bettini C; Moroff S; Breen M Vet Comp Oncol; 2017 Sep; 15(3):829-839. PubMed ID: 27198171 [TBL] [Abstract][Full Text] [Related]
3. Histologic grading of canine mast cell tumor: is 2 better than 3? Sabattini S; Scarpa F; Berlato D; Bettini G Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799 [TBL] [Abstract][Full Text] [Related]
4. Comparison of minichromosome maintenance protein 7, Ki67 and mitotic index in the prognosis of intermediate Patnaik grade cutaneous mast cell tumours in dogs. Berlato D; Murphy S; Laberke S; Rasotto R Vet Comp Oncol; 2018 Dec; 16(4):535-543. PubMed ID: 29989314 [TBL] [Abstract][Full Text] [Related]
5. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours. Moore AS; Frimberger AE; Taylor D; Sullivan N Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J Vet J; 2019 May; 247():71-74. PubMed ID: 30971355 [TBL] [Abstract][Full Text] [Related]
8. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours. Meyer A; Gruber AD; Klopfleisch R J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382 [TBL] [Abstract][Full Text] [Related]
9. Comparison between May-Grünwald-Giemsa and rapid cytological stains in fine-needle aspirates of canine mast cell tumour: Diagnostic and prognostic implications. Sabattini S; Renzi A; Marconato L; Militerno G; Agnoli C; Barbiero L; Rigillo A; Capitani O; Tinto D; Bettini G Vet Comp Oncol; 2018 Dec; 16(4):511-517. PubMed ID: 29961972 [TBL] [Abstract][Full Text] [Related]
10. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690 [TBL] [Abstract][Full Text] [Related]
11. Comparison of histologic margin status in low-grade cutaneous and subcutaneous canine mast cell tumours examined by radial and tangential sections. Dores CB; Milovancev M; Russell DS Vet Comp Oncol; 2018 Mar; 16(1):125-130. PubMed ID: 28544776 [TBL] [Abstract][Full Text] [Related]
12. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the global DNA methylation in canine mast cell tumour samples by immunostaining of 5-methyl cytosine. Morimoto CY; Tedardi MV; da Fonseca IIM; Kimura KC; Sanches DS; Epiphanio TF; de Francisco Strefezzi R; Dagli MLZ Vet Comp Oncol; 2017 Sep; 15(3):1014-1018. PubMed ID: 27140659 [TBL] [Abstract][Full Text] [Related]
14. Expression of Phosphorylated KIT in Canine Mast Cell Tumor. Halsey CHC; Thamm DH; Weishaar KM; Burton JH; Charles JB; Gustafson DL; Avery AC; Ehrhart EJ Vet Pathol; 2017 May; 54(3):387-394. PubMed ID: 28129097 [TBL] [Abstract][Full Text] [Related]
15. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685 [TBL] [Abstract][Full Text] [Related]
16. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Smith J; Kiupel M; Farrelly J; Cohen R; Olmsted G; Kirpensteijn J; Brocks B; Post G Vet Comp Oncol; 2017 Mar; 15(1):36-45. PubMed ID: 25643820 [TBL] [Abstract][Full Text] [Related]
17. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms. De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552 [TBL] [Abstract][Full Text] [Related]
18. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. Horta RS; Lavalle GE; Monteiro LN; Souza MCC; Cassali GD; Araújo RB Vet Pathol; 2018 Mar; 55(2):212-223. PubMed ID: 29338615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]